A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma. (February 2018)

• Record Type: Journal Article
• Authors: Offidani, Massimo; Corvatta, Laura
• Is Part Of: Future oncology. Volume 14:Number 4(2018)
• Page Start: 319
• Page End: 329
• Publication Date: 2018-02
• Subjects: elotuzumab -- lenalidomide -- monoclonal antibody -- multiple myeloma -- SLAMF7; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2017-0371
• Languages: English
• ISSNs: 1479-6694

Abstract

Monoclonal antibodies (mAb) represent a new frontier to treat newly diagnosed and relapsed-refractory multiple myeloma (MM). Elotuzumab, an mAb targeted SLAM7 in the plasma cells and natural killer cells surface, is the first mAb approved for the treatment of relapsed-refractory MM in combination with lenalidomide and dexamethasone. This approval was the final result of several preclinical and Phase I–II clinical studies leading to ELOQUENT-2 Phase III trial that demonstrated that elotuzumab adds a significant and durable value to standard therapy, paved the way of this new treatment strategy for MM. In this review we will describe elotuzumab mechanisms of action, clinical pharmacology and clinical studies that have led to these developments.